Stockscreener 앱 받기
21.51
0.83%
-0.18
전일 마감가:
$21.69
열려 있는:
$21.82
하루 거래량:
343.33K
Relative Volume:
0.36
시가총액:
$655.33M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-4.193
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-0.83%
1개월 성능:
+23.13%
6개월 성능:
+57.70%
1년 성능:
+16.71%
1일 변동 폭
$21.41
$21.91
1주일 범위
$20.78
$22.55
52주 변동 폭
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
21.51 | 660.81M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Responsive Playbooks and the KROS Inflection - news.stocktradersdaily.com
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - sharewise.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Stocks showing market leadership: Keros Therapeutics earns 92 RS rating - MSN
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc. - Defense World
Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Stocks to watch: Keros Therapeutics sees relative strength rating rise to 82 - MSN
Would You Still Hold Keros Therapeutics Stock If It Fell 30%? - Trefis
Can Keros Therapeutics Stock Hold Up When Markets Turn? - Trefis
Keros Therapeutics (NASDAQ:KROS) Trading Up 12%Here's Why - MarketBeat
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise - 富途牛牛
How Keros Therapeutics Inc. stock benefits from tech adoptionWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Franklin Resources Inc. Grows Stake in Keros Therapeutics, Inc. $KROS - Defense World
Will Keros Therapeutics Inc. stock outperform growth indexesBull Run & Fast Momentum Entry Tips - Newser
Top investors say Keros Therapeutics Inc (KROS) ticks everything they need - setenews.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - news.stocktradersdaily.com
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities - The Globe and Mail
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $19.00 at Bank of America - Defense World
B of A Securities Maintains Keros Therapeutics (KROS) Neutral Recommendation - Nasdaq
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
KROS or NVZMY: Which Is the Better Value Stock Right Now? - MSN
ExodusPoint Capital Management, LP's Strategic Acquisition of Ke - GuruFocus
Keros Therapeutics Reports Strong Revenue Growth - MSN
Keros Therapeutics Announces Final Results of Tender Offer - The Manila Times
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Latham & Watkins LLP
The Technical Signals Behind (KROS) That Institutions Follow - news.stocktradersdaily.com
Keros Therapeutics announces final results of tender offer - marketscreener.com
[SC TO-I/A] Keros Therapeutics, Inc. Amended Issuer Tender Offer | KROS SEC FilingForm SC TO-I/A - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - The Manila Times
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
Keros Therapeutics, Inc.'s Equity Buyback announced on October 20, 2025, has closed with 10,950,165 shares, representing 26.95% for $194.37 million. - marketscreener.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):